CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Short Interest Update

CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) was the target of a significant decline in short interest in February. As of February 28th, there was short interest totalling 4,800 shares, a decline of 25.0% from the February 13th total of 6,400 shares. Approximately 0.1% of the company’s stock are short sold. Based on an average daily volume of 8,600 shares, the days-to-cover ratio is currently 0.6 days.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $11.00 price objective on shares of CollPlant Biotechnologies in a research report on Friday, November 29th. D. Boral Capital reaffirmed a “buy” rating and issued a $14.00 price target on shares of CollPlant Biotechnologies in a report on Wednesday, February 12th.

CollPlant Biotechnologies Stock Performance

Shares of NASDAQ CLGN opened at $3.30 on Tuesday. CollPlant Biotechnologies has a fifty-two week low of $3.00 and a fifty-two week high of $6.75. The company has a market cap of $37.76 million, a PE ratio of -2.14 and a beta of 1.07. The business has a 50-day simple moving average of $3.66 and a two-hundred day simple moving average of $4.06.

Institutional Trading of CollPlant Biotechnologies

A number of institutional investors have recently bought and sold shares of CLGN. Benjamin Edwards Inc. acquired a new position in CollPlant Biotechnologies during the 3rd quarter valued at approximately $112,000. AMH Equity Ltd grew its holdings in shares of CollPlant Biotechnologies by 17.4% during the fourth quarter. AMH Equity Ltd now owns 116,500 shares of the company’s stock valued at $419,000 after buying an additional 17,295 shares during the last quarter. Renaissance Technologies LLC acquired a new position in shares of CollPlant Biotechnologies in the 4th quarter valued at $38,000. Finally, Wells Fargo & Company MN raised its stake in CollPlant Biotechnologies by 110.1% in the 4th quarter. Wells Fargo & Company MN now owns 8,405 shares of the company’s stock worth $30,000 after acquiring an additional 4,405 shares during the last quarter. 21.69% of the stock is currently owned by institutional investors and hedge funds.

About CollPlant Biotechnologies

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology.